title: Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia.
abstract: Adult T-cell leukemia (ATL) is a mature CD4+ T-cell malignancy etiologically associated with human T-cell leukemia virus type 1 (HTLV-1). Primary ATL cells frequently express CCR4 at high levels. Since HTLV-1 Tax does not induce CCR4 expression, transcription factor(s) constitutively active in ATL may be responsible for its strong expression. We identified an activator protein-1 (AP-1) site in the CCR4 promoter as the major positive regulatory element in ATL cells. Among the AP-1 family members, Fra-2, JunB and JunD are highly expressed in fresh primary ATL cells. Consistently, the Fra-2/JunB and Fra-2/JunD heterodimers strongly activated the CCR4 promoter in Jurkat cells. Furthermore, Fra-2 small interfering RNA (siRNA) or JunD siRNA, but not JunB siRNA, effectively reduced CCR4 expression and cell growth in ATL cells. Conversely, Fra-2 or JunD overexpression promoted cell growth in Jurkat cells. We identified 49 genes, including c-Myb, BCL-6 and MDM2, which were downregulated by Fra-2 siRNA in ATL cells. c-Myb, BCL-6 and MDM2 were also downregulated by JunD siRNA. As Fra-2, these proto-oncogenes were highly expressed in primary ATL cells but not in normal CD4+ T cells. Collectively, aberrantly expressed Fra-2 in association with JunD may play a major role in CCR4 expression and oncogenesis in ATL.
authors: Department of Microbiology, Kinki University School of Medicine, Osaka, Japan.
authors: T
authors: T
authors: Nakayama
authors: K
authors: K
authors: Hieshima
authors: T
authors: T
authors: Arao
authors: Z
authors: Z
authors: Jin
authors: D
authors: D
authors: Nagakubo
authors: A-K
authors: AK
authors: Shirakawa
authors: Y
authors: Y
authors: Yamada
authors: M
authors: M
authors: Fujii
authors: N
authors: N
authors: Oiso
authors: A
authors: A
authors: Kawada
authors: K
authors: K
authors: Nishio
authors: O
authors: O
authors: Yoshie
mesh_terms: D001665:Binding Sites; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D051921:Fos-Related Antigen-2 / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects / Q000502:physiology; D006801:Humans; D019169:Jurkat Cells; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000235:genetics* / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D016755:Proto-Oncogene Proteins c-jun / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D054398:Receptors, CCR4 / Q000235:genetics*
chemical_list: C515354:CCR4 protein, human; C497872:FOSL2 protein, human; D051921:Fos-Related Antigen-2; D016755:Proto-Oncogene Proteins c-jun; D034741:RNA, Small Interfering; D054398:Receptors, CCR4